EU/3/20/2294

About

On 26 June 2020, orphan designation EU/3/20/2294 was granted by the European Commission to IQVIA RDS Spain S.L., Spain, for sodium cromoglicate for the treatment of idiopathic pulmonary fibrosis.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2020 on request of the Sponsor.

Key facts

Active substance
Sodium cromoglicate
Disease / condition
Treatment of idiopathic pulmonary fibrosis
Date of first decision
26/06/2020
Outcome
Withdrawn
EU designation number
EU/3/20/2294

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

IQVIA RDS Spain S.L.
Calle De Juan Esplandiu 11 Planta 6
28007 Madrid
Spain
Tel. +34 918 066340
E-mail: iria.lara@iqvia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating